Radhika Tripuraneni - 02 Mar 2026 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Reporting relationship: Chief Medical Officer
Issuer ticker: VRDN
Reported as of: 02 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2026, 18:51:28 UTC
Prior SEC filing: 02 Feb 2026
Next SEC filing: 05 May 2026
Source filing: View source filing
Reporting owner signature: Jennifer Tousignant, Attorney-in-fact

Key filing fact

Radhika Tripuraneni filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 04 Mar 2026.

Key facts

This page summarizes Radhika Tripuraneni's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Mar 2026, 18:51.

Change

Previous filing in this sequence was filed on 02 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001761114 Primary reporting owner

Tripuraneni Radhika

Relationship: Chief Medical Officer
Address: C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 103A, WALTHAM
Signature: Jennifer Tousignant, Attorney-in-fact
Signature date: 04 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRDN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +95,800
Change %
Price: $0.000000^*
Shares after: 95,800
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 95,800
Exercise price: $30.25
Footnotes: F1

VRDN transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +19,150
Change %
Price: $0.000000^*
Shares after: 19,150
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,150
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

Footnote F2

Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

Footnote F3

The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.